WO2000042432A1 - Purification process using magnetic particles - Google Patents

Purification process using magnetic particles Download PDF

Info

Publication number
WO2000042432A1
WO2000042432A1 PCT/FI2000/000031 FI0000031W WO0042432A1 WO 2000042432 A1 WO2000042432 A1 WO 2000042432A1 FI 0000031 W FI0000031 W FI 0000031W WO 0042432 A1 WO0042432 A1 WO 0042432A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
medium
probe
magnetic
surface tension
Prior art date
Application number
PCT/FI2000/000031
Other languages
French (fr)
Inventor
Helena SEPPÄNEN
Pekka PALOMÄKI
Jukka Tuunanen
Timo KÄRMENIEMI
Original Assignee
Thermo Labsystems Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thermo Labsystems Oy filed Critical Thermo Labsystems Oy
Priority to JP2000593954A priority Critical patent/JP3546410B2/en
Priority to AT00901629T priority patent/ATE298087T1/en
Priority to DE60020810T priority patent/DE60020810T2/en
Priority to EP00901629A priority patent/EP1145010B1/en
Publication of WO2000042432A1 publication Critical patent/WO2000042432A1/en
Priority to NO20013541A priority patent/NO20013541L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B03SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03CMAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00Magnetic separation
    • B03C1/005Pretreatment specially adapted for magnetic separation
    • B03C1/01Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes

Definitions

  • the present invention relates to the purification of biological substances using magnetic particles which bind the material specifically from a mixture.
  • the invention can be used for instance for purifying nucleic acids DNA or RNA.
  • Magnetic particles can be coated with a separation reagent which reacts specifically with a desired biological substance.
  • the particles and the bound substance are separated from the mixture and thereafter the substance is released from the particles for further prosecution.
  • this is done in practice so that the particles are drawn with a magnet against the wall of the vessel containing the mixture, and the liquid is poured or sucked off the vessel. Thereafter a new liquid can be dispensed into the vessel.
  • Manual or automatic equipments for such separation technology are also commercially available (e.g., Spherotec, Inc., AutoMag Processor (USA), Merck Magnetic Rack (Darmstadt, Germany), PerSeptive Biosystems 96 well plate separator, Multi-6 Separator, Solo-Sep Separator (USA), Dynal Magnetic Particles Concentrators).
  • the old purification technique for DNA involves ultracentrifugation in a dense cesium chloride gradient.
  • magnetic particle technology described above has been used for purifying nucleic acids.
  • WO 94/18565 suggests a method and device for magnetic particle specific binding assay, in which magnetic particles are separated from a mixture by a probe comprising a rod movable in a vertical bore and provided with a magnet at the lower end thereof. The probe is pushed into the mixture with the rod in the lower position, whereby the particles are collected on the probe. Then the probe is transferred to another vessel and the rod is pulled in its upper position, whereby the particles are released.
  • all steps of the assay can be carried out in a separate vessel without having to transfer liquids. In the last vessel, a measurement is carried out.
  • WO 96/12959 suggests a magnetic particle transfer tool comprising an elongated body with a concavely tapered tip part.
  • the body further comprises means for providing a longitudinal magnetic field to collect particles to the tip of the body.
  • the magnetic field can be eliminated in order to release the particles.
  • This tool can be used especially for collecting particles from a large volume and releasing them into a very small volume.
  • material to be purified is dispensed in a first medium containing magnetic particles, which have been coated with a binding reagent for the material.
  • the binding reaction takes place, after which the particles are separated by means of a magnetic probe and transferred into a second medium, in which a desired further reaction necessary for the purification may take place.
  • the particles can be transferred similarly via further mediums for carrying out further steps of the purification process. All the vessels may contain the necessary reaction medium ready when the particles are transferred into it. Preferably the particles are also released from the probe in the second and subsequent mediums.
  • At least one of the mediums contains a surface tension releasing agent. This promotes the complete collection of the particles.
  • the invention can be used especially for purifying nucleic acids, such as ssDNA, dsDNA, and mRNA.
  • Figure 1 shows the effect of a detergent in collecting and releasing steps of magnetizable particles.
  • Figure 2 shows the effect of salt and saccharose in collecting and releasing buffer.
  • Figure 3 shows the effect of protein in collecting and releasing buffer.
  • Figure 4 shows the effect of a detergent when magnetic particles of different suppliers were used. Detailed description of the invention
  • the invention can be used for instance for the purification of cells, viruses, subcellular organelles, proteins, and especially nucleic acid materials.
  • the magnetic particles are preferably paramagnetic.
  • the size of the particles is usually less than 50 ⁇ m, preferably 0.1 - 10 ⁇ m, and most preferably 1 - 5 ⁇ m.
  • the concentration of the particles may be eg. 0.01 - 5 mg/ml, preferably 0.05 - 3 mg/ml, and most preferably 0.2 - 2 mg/ml.
  • the particles have been coated or treated with a binding reagent, eg. silicon, lectins and or other reactive functional groups such a oligonucleotides, antibodies, antigens, streptavidin, or biotin.
  • a binding reagent eg. silicon, lectins and or other reactive functional groups such a oligonucleotides, antibodies, antigens, streptavidin, or biotin.
  • the particles are preferably transferred from a vessel to another by using a probe comprising a rod movable in a vertical bore and provided with a magnet at the lower end thereof.
  • the probe is pushed into the mixture with the rod in the lower position, whereby the particles are collected on the probe. Then the probe is transferred to another vessel, and when the rod is pulled to its upper position the particles are released.
  • detergents are suitable.
  • Preferable detergents are ethoxylated anhydrosorbitol esters.
  • the esters may contain eg. about 4 - 20 ethylene oxide groups.
  • the concentration of a tenside may be eg. 0.001 - 0.5% (w/v), preferably 0.005 - 0.1% (w/v), and most preferably 0.01 - 0.05% (w/v).
  • the concentration of a protein may be eg. 0.1 - 10% (w/v), preferably 0.25 - 5% (w/v), and most preferably 0.5 - 2% (w/v).
  • the concentraion of a salt may be eg. 0.1 - 10 M, preferably 0.1 - 7 M.
  • the nucleic acids are immobilized by using magnetic particles.
  • the binding can be mediated by the interaction of streptavidin and biotin, whereby particles coated with streptavidin and biotinylated DNA can be used.
  • DNA can be adsorbed to the surface of the particles.
  • Oligo (dT) 25 covalently coupled to the surface of the particles.
  • the nucleic acids are washed several times to remove all the reaction components resulting from the amplification or other contaminants and, e.g., PCR inhibitors.
  • the washing can be performed by releasing and collecting complexes in a washing buffer and by transfering the complexes to another well containing fresh washing buffer.
  • the immobilized double-stranded DNA can be converted to a single-stranded by incubation with 0.1 M NaOH and using magnetic separation.
  • mRNA For the isolation of mRNA, it can be eluted from the particles by using a low salt buffer.
  • the purification process can be performed by a magnetic particle processor, in which all the mediums are ready in separate vessel.
  • a surface tension releasing compound is preferably used in each medium.
  • Suitable disposable plates, such as microtitration plates, comprising the necessaryy vessels can be used. In one plate, several parallel purifications can be accomplished.
  • Binding and Washing buffer 10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl, eg. 0.02% Tween 20 TM, 15 mM NaN 3 , pH 7.5 3.
  • TE buffer 10 m-M Tris-HCl, 1 mM EDTA, eg. 0.02% Tween 20 TM, 15 mM NaN 3 , pH 7.5
  • Lysis/binding buffer 100 mM Tris-HCl, pH 8.0, 500 mM LiCl, 10 mM EDTA, 1% LiDS, 5 mM dithiothreitol (DTT), 15 mM NaN 3 , (eg. 0.02% Tween 20 TM)
  • Washing buffer with LiDS 10 mM Tris-HCl, pH 8.0, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS, 15 mM NaN 3 (eg. 0.02% Tween 20 TM)
  • Washing buffer 10 mM Tris-HCl, pH 8.0, 0.15 M LiCl, 1 mM EDTA, eg. 0.02%) Tween 20 TM, 15 mM NaN 3
  • Reconditioning solution 0.1 M NaOH , eg. 0.02% Tween 20 TM
  • Storage buffer Oligo (dT) 25 250 mM Tris-Hcl, pH 8, 20 mM EDTA, 0.1% Tween-20, 15 mM NaN 3
  • Binding buffer 20 mM Tris-HCl, pH 7.5, 1.0 M LiCl, 2 mM EDTA, 15 mM NaN 3 , eg. 0.02% Tween 20 TM
  • Washing buffer 10 mM Tris-HCl, pH 8.0, 0.15 mM LiCl, 1 mM EDTA, 15 mM NaN 3 , eg. 0.02% Tween 20 TM
  • Particle suspension in Lysis buffer eg. 50 mM Tris-HCl, pH 7.2, 50 mM EDTA, 3% SDS, 1% 2-mercaptoethanol; 50 mM KCl, 10 - 20 mM Tris-HCl, 2.5 mM MgCl 2 , pH 8.3, 0.5 Tween 20 TM, 100 ⁇ g/ml Proteinase K; 100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 1% SDS, 500 ⁇ g ml Proteinase K) containing 15 mM NaN 3
  • Lysis buffer eg. 50 mM Tris-HCl, pH 7.2, 50 mM EDTA, 3% SDS, 1% 2-mercaptoethanol
  • 50 mM KCl 10 - 20 mM Tris-HCl, 2.5 mM MgCl 2 , pH 8.3, 0.5 Tween 20 TM, 100 ⁇ g/ml Proteinase K
  • the reagents are dispensed into a subsequent wells of a plate.
  • Example of a reagent configuration Well 1. Sample (biotinylated DNA, PCR amplicons) Well 2. Streptavidin coated magnetic particles in washing buffer Wells 3 - 5. Washing buffer Well 6. NaOH Well 7. TE buffer Well 8. Distilled water
  • Streptavidin coated magnetic particles (sizes: Scigen streptavidin 3 ⁇ m; Scigen; SPHEROTM streptavidin 4 - 4.5 ⁇ m, Spherotec, Dynabeads M-280 streptavidin 2.8 ⁇ m, Dynal) were saturated with biotinylated alkaline phosphatase (Calbiochem, San Diego, CA) for 1 h at +37 °C. Saturated particles were first washed to remove the unbound alkaline phosphatase and were then used to examine the effect of STRA in collecting and releasing steps of a magnetic particle processor. The instrument settings of these examples were adjusted from 20 ⁇ l to 200 ⁇ l and the capacity range of the processor was 1 - 24 samples per run. The processor utilized a rod magnet (cylindrical NdFeB axially magnetized, length 2 mm, width 3 mm) in polypropene tube (outer width 4.5 mm).
  • the particles were processed by releasing and collecting them from well to well so that the whole process comprised of 10 steps.
  • alkaline phosphatase saturated particles (0.016 ⁇ g - 1 ⁇ g particles / 10 ⁇ l diluent) were used as standards.
  • DEA diethanolamine
  • the substrate was incubated for 15 minutes at +37 °C with continuous shaking (900 rpm) in Labsystems iEMS Incubator/Shaker.
  • the reaction was stopped by adding 100 ⁇ l 1M NaOH into each well and the absorbances at 405 run were measured by photometer (Labsystems Multiskan).
  • the amount of remaining particles was determined from a linear standard curve and finally results were expressed as percentage of initial amount of particles (0.2 mg/well).
  • Fig 1. is shown the effect of detergent (Tween 20 TM) in different concentrations.
  • the degree of remaining particles (Scigen streptavidin) were over 3% / well, when surface tension releasing agent was not added into the collecting and releasing buffer.
  • the detergent concentration was > 0.00125%, the particles were collected efficiently.
  • Fig 2. is shown the effect of salt and saccharose in collecting and releasing buffer. By adding these components into the buffer, the collection of particles (Scigen streptavidin) was more efficient.
  • Fig 3. is shown the effect of a protein (casein) which was improving the collecting steps of particles (SPHEROTM streptavidin) in some degree.
  • Fig. 4 is shown the effect of detergent (Tween 20 TM) when the magnetic particles of different suppliers were used.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Soft Magnetic Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Iron (AREA)
  • Hard Magnetic Materials (AREA)
  • Water Treatment By Sorption (AREA)

Abstract

The invention relates to a process for the purification of a substance with magnetic particles treated with a reagent which binds the particles. After a binding reaction in a first medium, the particles and the substance bound to them are separated and transferred to a second medium. According to the invention, a surface tension releasing agent is dispensed at least the mediums before the particles are separated from it. This promotes the complete collection of the particles.

Description

PURIFICATION PROCESS USING MAGNETIC PARTICLES
Background of the invention
The present invention relates to the purification of biological substances using magnetic particles which bind the material specifically from a mixture. The invention can be used for instance for purifying nucleic acids DNA or RNA.
Magnetic particles can be coated with a separation reagent which reacts specifically with a desired biological substance. The particles and the bound substance are separated from the mixture and thereafter the substance is released from the particles for further prosecution. Nowadays this is done in practice so that the particles are drawn with a magnet against the wall of the vessel containing the mixture, and the liquid is poured or sucked off the vessel. Thereafter a new liquid can be dispensed into the vessel. Manual or automatic equipments for such separation technology are also commercially available (e.g., Spherotec, Inc., AutoMag Processor (USA), Merck Magnetic Rack (Darmstadt, Germany), PerSeptive Biosystems 96 well plate separator, Multi-6 Separator, Solo-Sep Separator (USA), Dynal Magnetic Particles Concentrators).
The old purification technique for DNA involves ultracentrifugation in a dense cesium chloride gradient. However, also magnetic particle technology described above has been used for purifying nucleic acids.
WO 94/18565 (Labsystems Oy) suggests a method and device for magnetic particle specific binding assay, in which magnetic particles are separated from a mixture by a probe comprising a rod movable in a vertical bore and provided with a magnet at the lower end thereof. The probe is pushed into the mixture with the rod in the lower position, whereby the particles are collected on the probe. Then the probe is transferred to another vessel and the rod is pulled in its upper position, whereby the particles are released. Thus all steps of the assay can be carried out in a separate vessel without having to transfer liquids. In the last vessel, a measurement is carried out.
WO 96/12959 (Labsystems Oy) suggests a magnetic particle transfer tool comprising an elongated body with a concavely tapered tip part. The body further comprises means for providing a longitudinal magnetic field to collect particles to the tip of the body. The magnetic field can be eliminated in order to release the particles. This tool can be used especially for collecting particles from a large volume and releasing them into a very small volume.
General description of the invention
Now a method according to claim 1 has been invented. Some preferable embodi- ments of the invention are defined in the other claims.
According to the invention, material to be purified is dispensed in a first medium containing magnetic particles, which have been coated with a binding reagent for the material. The binding reaction takes place, after which the particles are separated by means of a magnetic probe and transferred into a second medium, in which a desired further reaction necessary for the purification may take place. The particles can be transferred similarly via further mediums for carrying out further steps of the purification process. All the vessels may contain the necessary reaction medium ready when the particles are transferred into it. Preferably the particles are also released from the probe in the second and subsequent mediums.
According to the invention, at least one of the mediums contains a surface tension releasing agent. This promotes the complete collection of the particles.
Some of such agents have been used also before in this connection to promote the binding of the substance to be separated, see e.g. Wipat et al., Microbiology (1994), 140, 2067. In these known methods, the particles are not transferred from a vessel to another bu they are held on the wall of the vessel by means of a external magnet, while the medium is removed from the vessel.
The invention can be used especially for purifying nucleic acids, such as ssDNA, dsDNA, and mRNA.
Brief description of the drawings
The enclosed drawings form a part of the written description.
Figure 1 shows the effect of a detergent in collecting and releasing steps of magnetizable particles.
Figure 2 shows the effect of salt and saccharose in collecting and releasing buffer.
Figure 3 shows the effect of protein in collecting and releasing buffer. Figure 4 shows the effect of a detergent when magnetic particles of different suppliers were used. Detailed description of the invention
The invention can be used for instance for the purification of cells, viruses, subcellular organelles, proteins, and especially nucleic acid materials.
The magnetic particles are preferably paramagnetic. The size of the particles is usually less than 50 μm, preferably 0.1 - 10 μm, and most preferably 1 - 5 μm. The concentration of the particles may be eg. 0.01 - 5 mg/ml, preferably 0.05 - 3 mg/ml, and most preferably 0.2 - 2 mg/ml.
The particles have been coated or treated with a binding reagent, eg. silicon, lectins and or other reactive functional groups such a oligonucleotides, antibodies, antigens, streptavidin, or biotin.
The particles are preferably transferred from a vessel to another by using a probe comprising a rod movable in a vertical bore and provided with a magnet at the lower end thereof. The probe is pushed into the mixture with the rod in the lower position, whereby the particles are collected on the probe. Then the probe is transferred to another vessel, and when the rod is pulled to its upper position the particles are released.
Different kind of surface tension releasing compounds, especially water soluble compounds, can be used in the method. Examples of such are:
A. Tensides, such as - Soaps
- Detergents; including anionic, kationic, non-ionic and zwitterionic compounds
B. Alcohols, such as
- Polyethylene and polyvinyl alcohols and their protein etc. derivatives
C. Proteins D. Salts and carbohydrates in high concentrations, such as
- NaCl
- Saccharose
Also mixtures of compounds can be used.
Especially tensides such as detergents are suitable. Preferable detergents are ethoxylated anhydrosorbitol esters. The esters may contain eg. about 4 - 20 ethylene oxide groups.
The concentration of a tenside may be eg. 0.001 - 0.5% (w/v), preferably 0.005 - 0.1% (w/v), and most preferably 0.01 - 0.05% (w/v). The concentration of a protein may be eg. 0.1 - 10% (w/v), preferably 0.25 - 5% (w/v), and most preferably 0.5 - 2% (w/v). The concentraion of a salt may be eg. 0.1 - 10 M, preferably 0.1 - 7 M.
For purification of DNA or mRNA from different sources (for instance, DNA from PCR amplification; DNA from blood, bone marrow or cultured cells; mRNA from eucaryotic total RNA or from crude extracts of animal tissues, cells and plants) the nucleic acids are immobilized by using magnetic particles. The binding can be mediated by the interaction of streptavidin and biotin, whereby particles coated with streptavidin and biotinylated DNA can be used. In addition, DNA can be adsorbed to the surface of the particles. The binding of mRNA can be mediated by Oligo (dT)25 covalently coupled to the surface of the particles.
After the immobilization, the nucleic acids are washed several times to remove all the reaction components resulting from the amplification or other contaminants and, e.g., PCR inhibitors.
The washing can be performed by releasing and collecting complexes in a washing buffer and by transfering the complexes to another well containing fresh washing buffer.
For ssDNA purification the immobilized double-stranded DNA can be converted to a single-stranded by incubation with 0.1 M NaOH and using magnetic separation.
For the isolation of mRNA, it can be eluted from the particles by using a low salt buffer.
The purification process can be performed by a magnetic particle processor, in which all the mediums are ready in separate vessel. A surface tension releasing compound is preferably used in each medium. Suitable disposable plates, such as microtitration plates, comprising the necesary vessels can be used. In one plate, several parallel purifications can be accomplished.
Example of reagents used for a ssDNA purification
1. Particle suspension in eg. phosphate, Tris or Borate buffered saline, pH 7.4, containing 0.1% BSA, 15 mM NaN3 and eg. 0.02% polyoxyethylene (20) sorbitan monolaurate (Tween 20 ™) as a surface tension releasing agent
2. Binding and Washing buffer (TEN): 10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl, eg. 0.02% Tween 20 ™, 15 mM NaN3, pH 7.5 3. TE buffer: 10 m-M Tris-HCl, 1 mM EDTA, eg. 0.02% Tween 20 ™, 15 mM NaN3, pH 7.5
4. Melting solution: 0.1 M NaOH, eg. 0.02%o Tween 20 ™
5. eg. 0.02% Tween 20 ™ in distilled water, 15 mM NaN3
Example of reagents used for a mRNA direct purification
1. Oligo (dT)25 particle suspension in PBS, pH 7.4, containing eg. 0.02%> Tween 20 ™ and 15 mM NaN3
2. Lysis/binding buffer: 100 mM Tris-HCl, pH 8.0, 500 mM LiCl, 10 mM EDTA, 1% LiDS, 5 mM dithiothreitol (DTT), 15 mM NaN3 , (eg. 0.02% Tween 20 ™)
3. Washing buffer with LiDS (SDS): 10 mM Tris-HCl, pH 8.0, 0.15 M LiCl, 1 mM EDTA, 0.1% LiDS, 15 mM NaN3 (eg. 0.02% Tween 20 ™)
4. Washing buffer: 10 mM Tris-HCl, pH 8.0, 0.15 M LiCl, 1 mM EDTA, eg. 0.02%) Tween 20 ™, 15 mM NaN3
5. Elution solution: 2 mM EDTA, pH 8.0 , 15 mM NaN3, eg. 0.02% Tween 20 ™
6. Reconditioning solution: 0.1 M NaOH , eg. 0.02% Tween 20 ™
7. Storage buffer Oligo (dT)25: 250 mM Tris-Hcl, pH 8, 20 mM EDTA, 0.1% Tween-20, 15 mM NaN3
Example of the reagents used for a mRNA purification
1. Binding buffer: 20 mM Tris-HCl, pH 7.5, 1.0 M LiCl, 2 mM EDTA, 15 mM NaN3 , eg. 0.02% Tween 20 ™
2. Washing buffer: 10 mM Tris-HCl, pH 8.0, 0.15 mM LiCl, 1 mM EDTA, 15 mM NaN3, eg. 0.02% Tween 20 ™
5. Elution solution: 2 mM EDTA, pH 8.0 , 15 mM NaN3, eg. 0.02% Tween 20 ™
Example of reagents used for RNA isolation
1. 4 M guanidium isothiocyanate, 25 mM sodium citrate pH 7.0, 0.5% N-lauryl sarcosine, 0.01 M β-mercaptoethanol Example of reagents used for a DNA direct purification
1. Particle suspension in Lysis buffer (eg. 50 mM Tris-HCl, pH 7.2, 50 mM EDTA, 3% SDS, 1% 2-mercaptoethanol; 50 mM KCl, 10 - 20 mM Tris-HCl, 2.5 mM MgCl2, pH 8.3, 0.5 Tween 20 ™, 100 μg/ml Proteinase K; 100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 1% SDS, 500 μg ml Proteinase K) containing 15 mM NaN3
2. Washing buffer containing 15 mM NaN3 and eg. 0.02% Tween 20 ™
3. Resuspension buffer containing 15 mM NaN3 and eg. 0.02% Tween 20 ™
Example of the purification process of PCR products by a magnetic particle processor at room temperature
The reagents are dispensed into a subsequent wells of a plate.
Example of a reagent configuration: Well 1. Sample (biotinylated DNA, PCR amplicons) Well 2. Streptavidin coated magnetic particles in washing buffer Wells 3 - 5. Washing buffer Well 6. NaOH Well 7. TE buffer Well 8. Distilled water
Example of processing steps:
Well 2. Mixing, washing and collecting of particles, moving of them into well 3 Well 3. Washing of particles, moving of them into well 4
Well 4. Washing of particles, moving of them into well 1
Well 1. Sample incubation 10', moving of particles into well 4
Well 4. Washing of particles, moving of them into well 5
Well 5. Washing of particles, moving of them into well 6 Well 6. Incubation 5' in melting solution, moving of particles into well 4
Well 4. Washing of particles, moving of them into well 5
Well 5. Washing of particles, moving of them into well 7
Well 7. Rinsing of particles, moving of them into well 8
Well 8. Releasing of particles The effect of surface tension releasing agent (STRA) in collecting and releasing steps of magnetizable particles
Streptavidin coated magnetic particles (sizes: Scigen streptavidin 3 μm; Scigen; SPHERO™ streptavidin 4 - 4.5μm, Spherotec, Dynabeads M-280 streptavidin 2.8 μm, Dynal) were saturated with biotinylated alkaline phosphatase (Calbiochem, San Diego, CA) for 1 h at +37 °C. Saturated particles were first washed to remove the unbound alkaline phosphatase and were then used to examine the effect of STRA in collecting and releasing steps of a magnetic particle processor. The instrument settings of these examples were adjusted from 20 μl to 200 μl and the capacity range of the processor was 1 - 24 samples per run. The processor utilized a rod magnet (cylindrical NdFeB axially magnetized, length 2 mm, width 3 mm) in polypropene tube (outer width 4.5 mm).
Briefly, the particles were processed by releasing and collecting them from well to well so that the whole process comprised of 10 steps. The amount of particles, which remained into the wells after the collection, was estimated with alkaline phosphatase assay. Samples (10 μl) from each well were transferred to an empty microtitration plate (round-bottomed wells, width 6.5 mm).
In this assay alkaline phosphatase saturated particles (0.016 μg - 1 μg particles / 10 μl diluent) were used as standards. Into the wells containing 10 μl samples and standards were added 100 μl pNPP-substrate diluted in diethanolamine (DEA) buffer (Labsystems). The substrate was incubated for 15 minutes at +37 °C with continuous shaking (900 rpm) in Labsystems iEMS Incubator/Shaker. The reaction was stopped by adding 100 μl 1M NaOH into each well and the absorbances at 405 run were measured by photometer (Labsystems Multiskan).
The amount of remaining particles was determined from a linear standard curve and finally results were expressed as percentage of initial amount of particles (0.2 mg/well).
In Fig 1. is shown the effect of detergent (Tween 20 ™) in different concentrations. The degree of remaining particles (Scigen streptavidin) were over 3% / well, when surface tension releasing agent was not added into the collecting and releasing buffer. When the detergent concentration was > 0.00125%, the particles were collected efficiently. In Fig 2. is shown the effect of salt and saccharose in collecting and releasing buffer. By adding these components into the buffer, the collection of particles (Scigen streptavidin) was more efficient.
In Fig 3. is shown the effect of a protein (casein) which was improving the collecting steps of particles (SPHERO™ streptavidin) in some degree.
In Fig. 4 is shown the effect of detergent (Tween 20 ™) when the magnetic particles of different suppliers were used.

Claims

Claims
1. A process for the purification of a substance, wherein
- material containing the substance, and magnetic particles coated or treated with a reagent which binds the particles to the substance are dispensed in a first medium, - a binding reaction is let to take place, in which reaction the substance is bound to the particles, and
- a magnetic probe is pushed into the medium, whereby the particles adhere to the probe, and the probe together with the particles and the substance bound to them is transferred to a second medium, and if desired, separated from the second medium and transferred to a third medium, characterized in that
- a surface tension releasing agent is dispensed at least on of the mediums, preferably at least to the first medium, and most preferably to all mediums, before the probe and the particles are transferred from it.
2. A method according to claim 1, wherein the surface releasing compound is a tenside, alcohol, protein, or a salt or carbohydrate.
3. A method according to claim 1 or 2, wherein the surface tension releasing compound is a tenside, such as a detergent.
4. A method according to claim 3, wherein the concentration of the tenside is 0.001 - 0.5% (w/v), preferably 0.005 - 0.1%o (w/v), and most preferably 0.01 -
0.05% (w/v).
5. A method according to claim 1 or 2, wherein the surface tension releasing compound is a protein.
6. A method according to claim 5, wherein the concentration of the protein is 0.1 - 10% (w/v), preferably 0.25 - 5%o (w/v), and most preferably 0.5 - 2% (w/v).
7. A method according to claim 1 or 2, wherein the surface tension releasing compound is a salt.
8. A method according to claim 7, wherein the concentration of the salt is 0.1 - 10 M, preferably 0.1 - 7 M.
9. A method according to any of claims 1-8 for the prurification of cells, viruses, subcellular organelles, proteins, or nucleic acid materials.
10. A method according to claim 9 for the prurification of nucleic acid materials.
11. A method according to any of claims 1-10, wherein the size of the magnetic particles is less than 50 μm, preferably 0.1 - 10 μm, and most preferably 1 - 5 μm.
12. A method according to any of claims 1-11, wherein the concentration of the magnetic particles is 0.01 - 5 mg/ml, preferably 0.05 - 3 mg/ml, and most preferably
0.2 - 2 mg/ml.
13. A method for separating magnetic particles by means of a magnetic probe from a medium, characterized in that a surface tension releasing agent is dispensed into the medium before the particles are separated.
14. A method for improving the adherence of magnetic particles from a liquid medium to a magnetic probe to be pushed into the medium, characterized in that a surface tension releasing agent is dispensed into the medium before the particles are adherted to the probe.
PCT/FI2000/000031 1999-01-18 2000-01-18 Purification process using magnetic particles WO2000042432A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000593954A JP3546410B2 (en) 1999-01-18 2000-01-18 Purification method using magnetic particles
AT00901629T ATE298087T1 (en) 1999-01-18 2000-01-18 CLEANING METHOD USING MAGNETIC PARTICLES
DE60020810T DE60020810T2 (en) 1999-01-18 2000-01-18 CLEANING PROCEDURE USING MAGNETIC PARTICLES
EP00901629A EP1145010B1 (en) 1999-01-18 2000-01-18 Purification process using magnetic particles
NO20013541A NO20013541L (en) 1999-01-18 2001-07-17 Method of purification using magnetic particles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990082 1999-01-18
FI990082A FI990082A0 (en) 1999-01-18 1999-01-18 Purification process using magnetic particles

Publications (1)

Publication Number Publication Date
WO2000042432A1 true WO2000042432A1 (en) 2000-07-20

Family

ID=8553387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2000/000031 WO2000042432A1 (en) 1999-01-18 2000-01-18 Purification process using magnetic particles

Country Status (8)

Country Link
EP (1) EP1145010B1 (en)
JP (1) JP3546410B2 (en)
AT (1) ATE298087T1 (en)
DE (1) DE60020810T2 (en)
FI (1) FI990082A0 (en)
NO (1) NO20013541L (en)
RU (1) RU2239192C2 (en)
WO (1) WO2000042432A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069131A1 (en) * 1999-07-15 2001-01-17 QIAGEN GmbH Methods for separating particulate substrates from solution while minimizing particle loss
EP1108743A2 (en) * 1999-12-08 2001-06-20 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
WO2001079456A2 (en) * 2000-04-18 2001-10-25 Cancer Research Technology Limited Materials and methods relating to increasing viral titre
WO2003062462A2 (en) * 2002-01-16 2003-07-31 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
RU2630642C1 (en) * 2016-11-15 2017-09-11 Общество с ограниченной ответственностью "Научно Производственное Объединение ДНК-Технология" Device for allocation of nucleic acids
US9878323B2 (en) 2005-12-21 2018-01-30 Meso Scale Technologies, Llc Assay modules having assay reagents and methods of making and using same
US10794914B2 (en) 2005-12-21 2020-10-06 Meso Scale Technologies, Llc Assay apparatuses, methods and reagents

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033596A1 (en) * 2004-08-16 2006-03-30 Anatolij Ivanovich Malakhov Heat supply system
JP5845156B2 (en) * 2005-12-21 2016-01-20 メソ スケール テクノロジーズ エルエルシー Assay module comprising assay reagent, method for producing the same and method for using the same
US8222048B2 (en) 2007-11-05 2012-07-17 Abbott Laboratories Automated analyzer for clinical laboratory
PE20120524A1 (en) * 2008-12-11 2012-04-28 Basf Se ENRICHMENT OF MINERALS FROM MINING WASTE
RU2451747C2 (en) * 2009-08-13 2012-05-27 Закрытое акционерное общество "Научно-производственная фирма ДНК-Технология" Method for homogenising biological samples containing magnetic nanoparticles when extracting dna during automatic sample preparation for pcr analysis
US8475662B2 (en) * 2009-11-30 2013-07-02 Basf Se Modified HIMS process
US8784734B2 (en) 2010-05-20 2014-07-22 Abbott Laboratories Reusable sheaths for separating magnetic particles
RU2484139C1 (en) * 2012-05-17 2013-06-10 Общество с ограниченной ответственностью "Научно-Производственное Объединение ДНК-Технология" Device to extract nucleic acids
US11340244B2 (en) 2019-03-15 2022-05-24 Siemens Healthcare Diagnostics Inc. Method and apparatus for magnetic bead manipulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012959A1 (en) * 1994-10-20 1996-05-02 Labsystems Oy Magnetic particle transfer device
WO1996018731A2 (en) * 1994-12-12 1996-06-20 Dynal A/S Isolation of nucleic acid
US5705628A (en) * 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
WO1998031840A1 (en) * 1997-01-21 1998-07-23 Promega Corporation Methods of isolating biological target materials using silica magnetic particles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705628A (en) * 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
WO1996012959A1 (en) * 1994-10-20 1996-05-02 Labsystems Oy Magnetic particle transfer device
WO1996018731A2 (en) * 1994-12-12 1996-06-20 Dynal A/S Isolation of nucleic acid
WO1998031840A1 (en) * 1997-01-21 1998-07-23 Promega Corporation Methods of isolating biological target materials using silica magnetic particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANIL WIPAT ET AL.: "Monoclonal antibodies for Streptomyces lividans and their use for immunomagnetic capture of spores from soil", MICROBIOLOGY, vol. 140, 1994, pages 2067 - 2076, XP002927468 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
EP1069131A1 (en) * 1999-07-15 2001-01-17 QIAGEN GmbH Methods for separating particulate substrates from solution while minimizing particle loss
EP1108743A2 (en) * 1999-12-08 2001-06-20 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
EP1108743A3 (en) * 1999-12-08 2002-02-06 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
WO2001079456A2 (en) * 2000-04-18 2001-10-25 Cancer Research Technology Limited Materials and methods relating to increasing viral titre
WO2001079456A3 (en) * 2000-04-18 2003-04-24 Cancer Rec Tech Ltd Materials and methods relating to increasing viral titre
WO2003062462A3 (en) * 2002-01-16 2003-12-11 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
WO2003062462A2 (en) * 2002-01-16 2003-07-31 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US9878323B2 (en) 2005-12-21 2018-01-30 Meso Scale Technologies, Llc Assay modules having assay reagents and methods of making and using same
US10794914B2 (en) 2005-12-21 2020-10-06 Meso Scale Technologies, Llc Assay apparatuses, methods and reagents
US11065615B2 (en) 2005-12-21 2021-07-20 Meso Scale Technologies, Llc Assay modules having assay reagents and methods of making and using same
US11300571B2 (en) 2005-12-21 2022-04-12 Meso Scale Technologies, Llc. Assay apparatuses, methods and reagents
US11892455B2 (en) 2005-12-21 2024-02-06 Meso Scale Technologies, Llc. Assay apparatuses, methods and reagents
RU2630642C1 (en) * 2016-11-15 2017-09-11 Общество с ограниченной ответственностью "Научно Производственное Объединение ДНК-Технология" Device for allocation of nucleic acids

Also Published As

Publication number Publication date
ATE298087T1 (en) 2005-07-15
NO20013541D0 (en) 2001-07-17
EP1145010A1 (en) 2001-10-17
FI990082A0 (en) 1999-01-18
RU2239192C2 (en) 2004-10-27
DE60020810T2 (en) 2006-05-18
DE60020810D1 (en) 2005-07-21
JP3546410B2 (en) 2004-07-28
NO20013541L (en) 2001-09-17
JP2002535620A (en) 2002-10-22
EP1145010B1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
EP1145010B1 (en) Purification process using magnetic particles
JP7408229B2 (en) Polynucleotide capture materials and methods for their use
JP4856831B2 (en) Apparatus and method for mixing magnetic particles with a fluid
EP1058851B1 (en) Devide and method for transferring magnetic particles
US7972516B2 (en) Device and method for separating, mixing and concentrating magnetic particles with a fluid and use thereof in purification methods
JP4291247B2 (en) Methods for isolating nucleic acids
US9790250B2 (en) Method for isolating short-chain nucleic acids
US8202693B2 (en) Method of isolation of nucleic acids
US20050277204A1 (en) Sample preparation methods and devices
KR20190092617A (en) Lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids
JP6684868B2 (en) One-step method for purification of nucleic acids
JP2018524017A (en) Apparatus and method for extracting nucleic acid
JP2003501644A (en) Sample processing equipment
US20160046927A1 (en) Methods and systems for differential extraction
AU2011202810A1 (en) Device and method for separating, mixing and concentrating magnetic particles with a fluid and use thereof in purification methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP NO RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09646204

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593954

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000901629

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000901629

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000901629

Country of ref document: EP